Drug Profile
Befiradol - Neurolixis
Alternative Names: F-13,640; NLX 112Latest Information Update: 21 Mar 2023
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Developer Neurolixis; Pierre Fabre
- Class Antiparkinsonians; Non-opioid analgesics; Piperidines; Pyridines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Drug-induced dyskinesia
Highest Development Phases
- Phase II Diabetic neuropathies; Drug-induced dyskinesia
- Discontinued Cancer pain; Neuropathic pain